3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Keratosis, Actinic
25
Uterine Cervical Dysplasia
13
Melanoma
10
Carcinoma, Basal Cell
10
Glioma
6
Glioblastoma
6
Breast Neoplasms
5
Uterine Cervical Neoplasms
4
Neoplasm Metastasis
4
Condylomata Acuminata
4
Precancerous Conditions
3
Papillomavirus Infections
3
Keratosis
3
Hutchinson's Melanotic Freckle
3
Vulvar Neoplasms
2
Urinary Bladder Neoplasms
2
Squamous Intraepithelial Lesions
2
Non-Muscle Invasive Bladder Neoplasms
2
Neoplasms
2
Hemangioma, Capillary
2
HIV Infections
2
Ependymoma
2
Colorectal Neoplasms
2
Brain Neoplasms
2
Astrocytoma
2
Warts
1
Vulvar High Grade Squamous Intraepithelial Lesion (HSIL)
1
Virus Diseases
1
Vaginal Neoplasms
1
Stomach Neoplasms
1
Interventions
Oxaliplatin
46
Gemcitabine
45
Fluorouracil
40
Capecitabine
31
pembrolizumab
29
Leucovorin
29
Docetaxel
27
Cisplatin
25
Paclitaxel
23
Irinotecan
18
Carboplatin
18
Bevacizumab
18
130-nm albumin-bound paclitaxel
17
Pemetrexed
15
Albumin-Bound Paclitaxel
15
Radiotherapy
14
Nivolumab
12
Ramucirumab
11
Cyclophosphamide
11
Trastuzumab
8
Erlotinib Hydrochloride
8
Taxes
7
Radiosurgery
7
Drug Therapy
7
cemiplimab
6
zolbetuximab
5
trastuzumab deruxtecan
5
regorafenib
5
durvalumab
5
Sorafenib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Adenocarcinoma
×
Imiquimod
×
Clear all
NCT02234921
2018-10-11
DRibble
UbiVac
Phase 1
Completed
3 enrolled